BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
Official title: BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
Funded at Wistar Institute · NIH-11515077 · Data updated 2026-11-12
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 16, 2021 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $5,586,045 |
| NIH project number | 4UM1AI164570-06 |
| Project ID | NIH-11515077 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who have or could participate in future translational trials and biorepository studies.
✕Less likely to help
Individuals not eligible for future translational trials or those who cannot participate in long-term immunotherapy regimens may not benefit.
What this research studies
This program brings together experts to understand how HIV hides in the body and how immune cells can be programmed to control or eliminate the virus. It uses strategies like broadly neutralizing antibodies, engineered immune cells, and nanoparticle therapies in a coordinated plan. The project includes laboratory studies, animal models, and a clinical trial development link to translate promising findings to people living with HIV. A dedicated clinical biorepository and community engagement component will ensure patient samples and ethics considerations support progress.
Why it matters
Potential benefit: If successful, the work could lead to durable HIV remission or eradication strategies that reduce or eliminate the need for ongoing ART.
How similar studies have gone: Previous HIV cure research shows that immune-based strategies can contribute to viral control, but durable remission remains elusive; BEAT-HIV is designed to build on these insights with a comprehensive, multi-pronged approach.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Montaner, Luis J — Wistar Institute
- Study coordinator: Montaner, Luis J
Related research
Other NIH-funded projects on the same topics.
-
BEAT-HIV: Combination Treatments to Cure HIV-1 Infection
This project looks for new ways to cure HIV-1 infection by combining different immune-boosting treatments.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.